注意欠陥多動性障害の世界市場-2022-2029年

市場力学

精神疾患治療のための健康保険へのアクセス向上とADHDの発症率上昇

メンタルヘルス治療のための健康保険へのアクセス増加により、市場の成長が見込まれています。

健康保険は、将来の外科手術や医療費に対する保険と定義されています。これは、個人または人々のグループが彼らの健康保険のために事前に購入保険料と呼ばれる手数料を支払うことにより、契約です。保険の種類によって、被保険者がポケットから医療費を支払い、保険会社がそれを払い戻すか、保険会社がサービス提供者に直接支払うかのどちらかになります。国民精神保健調査（NMHS）のデータによると、精神障害は、収入が少なく、雇用が限られ、教育レベルが低い世帯で著しく高く、したがって精神障害に対してより脆弱であることが明らかです。同時に、これらの同じ要因が、精神保健サービスへのアクセスや利用を制限しています。

ADHDの発症率の上昇は、市場成長の原動力になると予想されます。

ADHDの有病率は世界的に大きく変動しており、診断基準や使用する評価ツールによって、1%という低い値から20%近くまで幅があります。世界全体の推定有病率は5.3%で、ADHDは子どもに最も多く見られる精神疾患です。ADHD（注意欠陥多動性障害）は、障害による総喪失年数の0.06％、総死亡者数の0.02％に相当します。ADHDに起因する負担の大部分は小児期に発生します。ADHDに起因する負担の大きさは、早期介入と治療の観点から、政策立案者の注意を引く必要があります。

注意欠陥多動性障害（ADHD）は、小児期および思春期に最もよく見られる神経発達障害であり、学齢期の子どもおよび青年全体の2.2～17.8%が罹患しています。小児のADHDは、学習または実行機能の制御の制限、社会的スキルの全体的な障害など、幅広い発達障害と関連しています。

ADHD治療薬に伴う副作用は、市場成長の妨げになると予想されます。

ADHDの症状を軽減する上で、覚醒剤は非常に効果的ですが、一部の子どもたちは不快な副作用や有害な副作用を経験します。副作用が問題になった場合、医師は子供が服用する薬の量や放出方式、種類を変更しようとします。目標は、副作用を最小限に抑えながら、何が有効かを理解することです。寝つきが悪いのは、就寝時に刺激が強すぎるためで、しばしばコンピューターで何かをすることで気持ちを落ち着かせていることもあります。薬が切れた場合、ADHDは彼らが目を覚まし続けるかもしれません。

別のADHD薬、atomoxetine（ストラテラ）、覚せい剤ではないが、大人と不規則な心拍にリンクされています。FDAは、これらの問題の履歴を持つ人々は他の人から離れて滞在を示唆しています。ADHD薬いくつかの精神的な問題に接続されている可能性がありますが、それはまれです。たとえば、何人かの人々は、攻撃性と敵意のような行動の問題を報告しています。対照的に、他の人は双極性障害の症状を開発しました。また、FDAは、刺激性ADHD治療薬が、幻聴や気分の落ち込み、パラノイアといった精神病の症状につながる危険性がわずかにあることを警告しています。

COVID-19の影響分析

いくつかのプロトコルのため、COVID-19のパンデミック時に医療行為が影響を受けています。このパンデミックに関わる注意欠陥多動性障害（ADHD）の問題の診断とモニタリングの手順が影響を受けているのです。人々はADHDの治療を受けたり、COVID-19のリスクのために薬を購入することを恐れているように、注意欠陥多動性障害（ADHD）市場への影響がありました。

産業分析

注意欠陥多動性障害市場は、アンメットニーズ、価格分析、サプライチェーン分析、規制分析など、さまざまな業界要因に基づく市場の詳細な分析を提供します。

世界の注意欠陥多動性障害市場レポートでは、約45+市場データ表、40+図、180ページの構成で提供しています。

目次

第1章 調査手法と調査範囲

• 調査手法
• 調査目的および調査範囲

第2章 市場の定義と概要

第3章 エグゼクティブサマリー

• 薬物タイプ別市場内訳
• 年齢層別市場内訳
• 流通チャネル別市場内訳

第4章 市場力学

• 市場影響要因
  • 促進要因
    • 精神疾患治療のための健康保険へのアクセス増加
    • 注意欠陥多動性障害（ADHD）の発症率の上昇により、注意欠陥多動性障害（ADHD）市場が拡大する
  • 抑制要因
    • ADHD治療薬に伴う副作用が注意欠陥多動性障害（ADHD）市場の阻害要因となります。
  • ビジネスチャンス
  • 影響分析

第5章 産業分析

• ポーターのファイブフォース分析
• 疫学分析
• サプライチェーン分析
• 価格設定分析
• 規制分析
• 保険償還の分析
• アンメットニーズ

第6章 COVID-19の分析

• COVID-19の市場分析
  • COVID-19以前の市場シナリオ
  • COVID-19の現在の市場シナリオ
  • COVID-19の後、あるいは将来のシナリオ
• COVID-19の中での価格ダイナミクス
• 需要-供給スペクトラム
• パンデミック時の市場に関連する政府の取り組み
• メーカーの戦略的な取り組み
• まとめ

第7章 薬剤タイプ別

• 覚醒剤
• 非刺激剤

第8章 年齢層別

• 小児・思春期
• 成人

第9章 流通チャネル別

• 小売薬局
• eコマース

第10章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • イタリア
  • スペイン
  • その他欧州
• 南米
  • ブラジル
  • アルゼンチン
  • その他の南米地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • オーストラリア
  • その他アジア太平洋地域
• 中東・アフリカ地域

第11章 競合情勢

• 主な展開と戦略
• 企業シェア分析
• 製品ベンチマーク
• 注目の主要企業リスト
• 破壊的技術を持つ企業リスト
• スタートアップ企業リスト

第12章 企業プロファイル

• Supernus Pharmaceuticals, Inc.
  • 企業の概要
  • 製品ポートフォリオと内容
  • 主なハイライト
  • 財務概要
• Pfizer Inc
• Novartis AG
• Eli Lilly and Company
• GlaxoSmithKline PLC
• Mallinckrodt Pharmaceuticals
• Johnson & Johnson
• Hisamitsu Pharmaceutical Co., Inc.,
• Chongqing Fujin Biology Medical Company
• Wanbang Medical Company LIST NOT EXHAUSTIVE

第13章 DataM

Market Oveview

Attention-Deficit Hyperactivity Disorder Market size was valued US$ YY million in 2021 and is estimated to reach US$ YY million by 2029, growing at a CAGR of 7.0% during the forecast period (2022-2029).

Attention-deficit hyperactivity disorder (ADHD) is a disorder that is marked by an ongoing pattern of hyperactivity-impulsivity and inattention that interferes with functioning or development.

Market Dynamics

The increasing access to health insurance for mental health treatment and rising incidence of ADHD.

The increasing access to health insurance for mental health treatment is expected to drive market growth.

Health insurance is defined as insurance for future surgical or medical expenditures. It is a contract where an individual or group of people by paying a fee called the premium purchase in advance for their health coverage. Based on the type of plan, usually, the insured person is either required to pay for the health expenses from their pocket, which the insurance company then reimburses or the expenses are directly paid by the insurance provider who pays it to the service provider. Data from the National Mental Health Survey (NMHS) reveal that mental disorders are significantly higher in households with lesser income, limited employment, and low levels of education, thus making it evident that they have a greater vulnerability to mental disorders. At the same time, these same factors also limit their access to and utilization of mental health services.

The rising incidence of ADHD is expected to drive market growth.

The prevalence of ADHD is highly variable worldwide, ranging from as low as 1% to nearly 20%, depending on the diagnostic criteria and the assessment tools used. With an estimated worldwide-pooled prevalence of 5.3%, ADHD is the most prevalent mental disorder in children. ADHD (attention-deficit hyperactive disorder) is responsible for 0.06% of total years lost to disability and 0.02% of total DALYs. The majority of the burden due to ADHD occurs in childhood. The magnitude of the burden attributable to ADHD needs the attention of policymakers in terms of early intervention and treatment.

Attention-deficit hyperactivity disorder (ADHD) is the most common neurodevelopmental disorder in childhood and adolescence, affecting 2.2 to 17.8% of all school-aged children and adolescents. ADHD in children has been associated with a wide range of developmental deficits, including limitations of learning or control of executive functions and global impairments of social skills.

Side effects associated with ADHD drugs are expected to hamper market growth.

In reducing symptoms of ADHD, stimulant medications can be very effective, but some kids experience uncomfortable or harmful side effects. When side effects become a problem, doctors try to change the dosage, the release formula, or the type of medication a child takes. The goal is to understand what will benefit them with the least side effects. Trouble sleep may also be caused by kids being too stimulated at bedtime, often by doing something on the computer to calm themselves. Their ADHD may keep them awake if the medication has worn off.

Another ADHD medication, atomoxetine (Strattera), isn't a stimulant but has been linked to adults and irregular heartbeats. The FDA suggests people with a history of these problems stay away from others. ADHD drugs may be connected to some mental health issues, but it's rare. For instance, some people have reported behavior problems like aggression and hostility. In contrast, others developed symptoms of bipolar disorder. The FDA also warned that there's a slight risk that stimulant ADHD drugs could lead to symptoms of psychosis-like hearing things or mood swings and paranoia.

COVID-19 Impact Analysis

Due to several protocols, medical practices have been affected during the COVID-19 pandemic. The procedures for diagnosis and monitoring attention deficit hyperactivity disorder (ADHD) problems involved in this pandemic have been affected. As people are scared to undergo therapies for ADHD or even buy the medication due to the risk of COVID-19, there has been an impact on the attention deficit hyperactivity disorder (ADHD) market.

Industry Analysis

The attention-deficit hyperactivity disorder market provides in-depth analysis of the market based on various industry factors such as unmet needs, pricing analysis, supply chain analysis, regulatory analysis etc.

Segment Analysis

Stimulants segment is expected to hold the largest market share in the attention-deficit hyperactivity disorder Market

Stimulants effectively manage ADHD symptoms such as short attention span, impulsive behavior, and hyperactivity. Many stimulants are available: short-acting (immediate-release), intermediate-acting, and long-acting. The commonly used treatment for Attention-Deficit Disorder/ Hyperactivity Disorder is stimulant therapy. Stimulants effectively manage ADHD symptoms such as impulsive behavior, short attention span, and hyperactivity. They may be used alone or in combination with behavior therapy. These drugs improve ADHD symptoms in about 70% of adults and 70% to 80% of children shortly after starting treatment. Improvements include reduced interrupting, fidgeting, and other hyperactive symptoms, home relationships, and improved task completion. Improvements in behavior and attention span usually continue as long as the medication is taken. However, social adjustment and school performance benefits have not yet been shown to endure over the long term.

Currently, the most commonly prescribed medications for ADHD are stimulant drugs (psychostimulants). Stimulants appear to boost and balance levels of brain chemicals called neurotransmitters. These medications help improve the signs and symptoms of inattention and hyperactivity, sometimes in a short period. Amphetamines include dextroamphetamine (Dexedrine),dextroamphetamine-amphetamine, and lisdexamfetamine (Vyvanse). Stimulant drugs are available in long-acting and short-acting forms. A long-acting patch of methylphenidate (Daytrana) is available that can be worn on the hip.

The pediatric and Adolescents segment will dominate the attention deficit hyperactivity disorder (ADHD)

Estimates suggest that about 4% to 12% of children have ADHD. Boys are 2 to 3 times more likely to have ADHD of the hyperactive or combined type than girls. In the U.S, around 6.1 million children (9.4 percent) between the ages of 2 to 17 are estimated to have been diagnosed with attention deficit hyperactivity disorder (ADHD or ADD).

The American Psychiatric Association (APA) stated that 5 % of children in America have ADHD. But the Centers for Disease Control and Prevention (CDC) put the number at more than double the APAs. According to the CDC, 11 percent of American children, ages 4 to 17, have an attention disorder. Approximate 8.4% of children and 2.5% of adults have ADHD. ADHD is first identified in school-aged children when it leads to disruption in the classroom or problems with schoolwork. ADHD from childhood is a chronic health problem with a significant risk for mortality, the persistence of ADHD, and long-term morbidity in adulthood. Though ADHD has been reported to affect 4.4% of adults, the estimation of the persistence of ADHD from childhood to adulthood has varied widely, ranging from 6% to 66.

Retail Pharmacies segment will dominate the attention deficit hyperactivity disorder (ADHD)

Attention-deficit hyperactivity disorder (ADHD) medications are subject to abuse, misuse, and diversion. Obtaining ADHD prescriptions from multiple prescribers or filled across multiple pharmacies, known as 'doctor shopping,' may reflect such unsanctioned use. No clinical guidelines exist to guide dosing or indications for use, making it difficult to have a standardized treatment approach, especially with differing state regulations. Instead of traditional pharmacies, patients seeking marijuana for medicinal use often go to dispensaries. Some dispensaries focus on stocking and selling only recreational or medicinal products, while others offer both.

Retail Pharmacies would be the safest place for dispensing attention-deficit hyperactivity disorder (ADHD) medications. Pharmacists are experts in medication and play a significant role in dispensing and monitoring medication to ensure safe and optimal use. Dispensing, like other ADHD medications, through a pharmacy is the safest option.

Geographical Analysis

North American region is expected to hold the largest market share in the global attention-deficit hyperactivity disorder market.

A behavioral disorder Attention-deficit hyperactivity disorder (ADHD) affects up to 1 in 20 children in the USA. The predominance of American research into this disorder over the past 40 years has led to the impression that ADHD is largely an American disorder and is much less prevalent elsewhere.

ADHD isn't just a childhood disorder. About 4% of American adults over the age of 18 contend with ADHD behaviors daily. In adulthood, it's diagnosed equally between males and females. During their lifetimes, 13% of men will be diagnosed with ADHD, while just 4.2% of women will be diagnosed. Current prevalence rates of ADHD vary between states, with Nevada having the lowest rate at 4.2% and Kentucky having the highest rate of 14.8%. In addition, due to the launch of products by regional players. For instance, Adlon Therapeutics L.P., a subsidiary of Purdue Pharma L.P., received U.S. regulatory approval in March 2019. Food and Drug Administration (FDA) for Adhansia XR (methylphenidate hydrochloride) extended-release capsules CII for the treatment of attention deficit hyperactivity disorder (ADHD) in patients six years of age and older. Thus, from the above statements, the North American region accounted for the largest market share in the forecast period.

Competitive Landscape

Major key players in the attention-deficit hyperactivity disorder market are Pfizer Inc., Novartis AG, Eli Lilly and Company, GlaxoSmithKline PLC, Mallinckrodt Pharmaceuticals, Johnson & Johnson, UCB S.A., Hisamitsu Pharmaceutical Co., Inc., Purdue Pharma L.P. and Supernus Pharmaceuticals, Inc.

Supernus Pharmaceuticals, Inc.:

Overview:

Supernus Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing products for treating central nervous system (CNS) diseases. Their extensive expertise in product development has been built over the past 30 years. Initially as a standalone development organization, then as a U.S. subsidiary of Shire plc is Supernus Pharmaceuticals Inc. They market products in the United States through their specialty sales force and seek strategic collaborations with other pharmaceutical companies to license products outside the United States.

Product Portfolio:

The company is developing several product candidates to address large market opportunities in the CNS market, including SPN-812 for the treatment of ADHD in adults, apomorphine infusion pump for hypomobility in PD, SPN-820 (NV-5138) for treatment-resistant depression, and SPN-817 for the treatment of epilepsy.

Key Development:

The U.S. Food and Drug Administration (FDA) approved Qelbree, the first new non-stimulant medication for the treatment of attention deficit hyperactivity disorder (ADHD) in children and adolescents in more than 10 years. Manufactured by Supernus Pharmaceuticals, Inc. Qelbree (viloxazine extended-release capsules) is a selective norepinephrine reuptake inhibitor-a class of drugs often used to treat anxiety and depression, and sometimes ADHD. Qelbree is approved to treat young people with ADHD between the ages of 6 and 17 years.

The global attention-deficit hyperactivity disorder market report would provide an access to an approx. 45+market data table, 40+figures and 180pages.

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

• 3.1. Market Snippet By Drug Type
• 3.2. Market Snippet By Age Group
• 3.3. Market Snippet By Distribution Channel

4. Market Dynamics

• 4.1. Market Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Increasing access to health insurance for mental health treatment
    • 4.1.1.2. The rising incidence of ADHD will drive the attention deficit hyperactivity disorder (ADHD) market
  • 4.1.2. Restraints:
    • 4.1.2.1. Side-effects associated with ADHD drugs will hamper the attention deficit hyperactivity disorder (ADHD) market
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Forces Analysis
• 5.2. Epidemiology Analysis
• 5.3. Supply Chain Analysis
• 5.4. Pricing Analysis
• 5.5. Regulatory Analysis
• 5.6. Reimbursement Analysis
• 5.7. Unmet Needs

6. COVID-19 Analysis

• 6.1. Analysis of Covid-19 on the Market
  • 6.1.1. Before COVID-19 Market Scenario
  • 6.1.2. Present COVID-19 Market Scenario
  • 6.1.3. After COVID-19 or Future Scenario
• 6.2. Pricing Dynamics Amid Covid-19
• 6.3. Demand-Supply Spectrum
• 6.4. Government Initiatives Related to the Market During Pandemic
• 6.5. Manufacturers Strategic Initiatives
• 6.6. Conclusion

7. By Drug Type

• 7.1. Introduction
  • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type Segment
  • 7.1.2. Market Attractiveness Index, By Drug Type Segment
• 7.2. Stimulant*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis, US$ Million, 2018-2029 and Y-o-Y Growth Analysis (%), 2020-2029
• 7.3. Non-stimulant

8. By Age Group

• 8.1. Introduction
  • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Age Group
  • 8.1.2. Market Attractiveness Index, By Age Group
• 8.2. Pediatric and Adolescents*
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis, US$ Million, 2018-2029 and Y-o-Y Growth Analysis (%), 2020-2029
• 8.3. Adults

9. By Distribution Channel

• 9.1. Introduction
  • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel Segment
  • 9.1.2. Market Attractiveness Index, By Distribution Channel Segment
• 9.2. Retail Pharmacies *
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis, US$ Million, 2018-2029 and Y-o-Y Growth Analysis (%), 2020-2029
• 9.3. E-Commerce

10. By Region

• 10.1. Introduction
  • 10.1.1. Market Size Analysis, US$ Million, 2018-2029 and Y-o-Y Growth Analysis (%), 2020-2029, By Region
  • 10.1.2. Market Attractiveness Index, By Region
• 10.2. North America
  • 10.2.1. Introduction
  • 10.2.2. Key Region-Specific Dynamics
  • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), ByType
  • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Age Group
  • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 10.2.6.1. U.S.
    • 10.2.6.2. Canada
    • 10.2.6.3. Mexico
• 10.3. Europe
  • 10.3.1. Introduction
  • 10.3.2. Key Region-Specific Dynamics
  • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), ByType
  • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Age Group
  • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 10.3.6.1. Germany
    • 10.3.6.2. U.K.
    • 10.3.6.3. France
    • 10.3.6.4. Italy
    • 10.3.6.5. Spain
    • 10.3.6.6. Rest of Europe
• 10.4. South America
  • 10.4.1. Introduction
  • 10.4.2. Key Region-Specific Dynamics
  • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
  • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Age Group
  • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 10.4.6.1. Brazil
    • 10.4.6.2. Argentina
    • 10.4.6.3. Rest of South America
• 10.5. Asia Pacific
  • 10.5.1. Introduction
  • 10.5.2. Key Region-Specific Dynamics
  • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), ByType
  • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Age Group
  • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 10.5.6.1. China
    • 10.5.6.2. India
    • 10.5.6.3. Japan
    • 10.5.6.4. Australia
    • 10.5.6.5. Rest of Asia Pacific
• 10.6. Middle East and Africa
  • 10.6.1. Introduction
  • 10.6.2. Key Region-Specific Dynamics
  • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), ByType
  • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Age Group
  • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

11. Competitive Landscape

• 11.1. Key Developments and Strategies
• 11.2. Company Share Analysis
• 11.3. Product Benchmarking
• 11.4. List of Key Companies to Watch
• 11.5. List of Company with disruptive technology
• 11.6. List of Start Up Companies

12. Company Profiles

• 12.1. Supernus Pharmaceuticals, Inc.*
  • 12.1.1. Company Overview
  • 12.1.2. Product Portfolio and Description
  • 12.1.3. Key Highlights
  • 12.1.4. Financial Overview
• 12.2. Pfizer Inc
• 12.3. Novartis AG
• 12.4. Eli Lilly and Company
• 12.5. GlaxoSmithKline PLC
• 12.6. Mallinckrodt Pharmaceuticals
• 12.7. Johnson & Johnson
• 12.8. Hisamitsu Pharmaceutical Co., Inc.,
• 12.9. Chongqing Fujin Biology Medical Company
• 12.10. Wanbang Medical Company LIST NOT EXHAUSTIVE

13. DataM Intelligence

• 13.1. Appendix
• 13.2. About Us and Services
• 13.3. Contact Us